Ocular Hypotensive Effects of Sacubitril and Valsartan Eye Drops on Ocular Normotensive and Betamethasone-Induced Ocular Hypertensive Rabbits

Abstract

Background: Glaucoma is a neurodegenerative disorder affecting the eye and is accompanied by elevated intraocular pressure
(IOP). Patients may gradually lose their visual field if neglected and even go entirely blind. treatment of glaucoma may in involve
surgical, laser therapy, and pharmacological treatment, regarding last, adrenergic agonists, carbonic anhydrase inhibitors, betablockers, and other common topical ocular therapies for POAG lower IOP by inhibiting the frequency of AH production or by
accelerating AH draining through an unorthodox (uveoscleral) outflow channel (e.g. prostaglandin analogs).
Aim of the Study: This present study aimed to explore the efficacy of topically applied sacubatril/valsartan 0.5% eye drop on
ocular normotensive and betamethasone-induced ocular hypertensive rabbits.
Material and Method: A total of 48 apparently healthy rabbits were included in the present study. They were examined regularly
and were kept in a standard laboratory environment. They were provided with fresh water and a diet. The animals were also kept
under a light cycle of 12 hours. Animals are equally divided into two major groups the Normotensive group (24 rabbits) and the
betamethasone-induced ocular hypertensive group (24 rabbits) each of them is subdivided into four groups each one containing
six rabbits.1- vehicle group 20 latanoprost group 3-valsartan group 4- sacubatril/valsartan group The intraocular pressure was
measured for both eyes with the aid of a Schiötz tonometer according to the instructions of the manufacturer. The other examined
parameters were pupil diameter, light pupillary reflex, corneal sensation reflex, and conjunctival redness. Histopathological
examination also will include in this study.
Result: this study showed that valsartan is effective in reducing the IOP of both normotensive and betamethasone-induced ocular
hypertensive eye meanwhile still not comparable to the latanoprost efficacy. The study also revealed that sacubatril/valsartan causes a significant IOP lowering effect in both groups compared to the vehicle group and also comparable to latanoprost efficacy. Both sacubatril / valsartan and valsartan alone showed more safety profile than latanoprost. Histopathological examination revealed that the level of the Amyloid beta in the retina has no change and so no degenerative changes showed in the macula after 21 days of treatment with sacubatril/valsartan.
Conclusion: Sacubitril/valsartan eye drops significantly reduced the IOP with minimum side effects and a clinical trial is required
to evaluate its efficacy in the treatment of glaucoma.